IBEX 35
11.304,70 -34,80 (-0,31%) Euro Stoxx 50
5.033,16 -41,18 (-0,81%) Dólar/Euro
1,0859 -0,0002 (-0,02%) Petróleo Brent
82,71 -1,00 (-1,19%) Oro
2.426,60 -11,90 (-0,49%) Bitcoin EUR
65.559,79 +3.807,34 (+6,17%)
ABVC BioPharma, Inc. (ABVC)
Antes de la apertura:
ABVC BioPharma, Inc.
44370 Old Warm Springs Boulevard
Fremont, CA 94538
United States
(510)-668-0881
https://www.abvcpharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 16
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Eugene Jiang | Chairman & Chief Business Officer | 200k | N/A | 1986 |
| Dr. Uttam Yashwant Patil Ph.D. | Chief Executive Officer | N/A | N/A | 1986 |
| Mr. Leeds Chow | CFO & Principal Accounting Officer | 180k | N/A | 1989 |
| Dr. Tsung-Shann Jiang EMBA, Ph.D. | Chief Scientific Officer, Chief Strategy Officer & Director | 200k | N/A | 1954 |
Descripción
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Gobierno corporativo
El ISS Governance QualityScore de ABVC BioPharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
